lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

MAGAE3 Expression in Solid/Non-Solid Human Tumor: A Meta-Analysis

22 Pages Posted: 26 Jun 2020

See all articles by Haoran Jiang

Haoran Jiang

First Clinical College,Wenzhou Medical University

Lihao Zhao

Department of Chemoradiation Oncology, the First Affiliated Hospital of Wenzhou Medical University

Han Yang

Department of Chemoradiation Oncology, the First Affiliated Hospital of Wenzhou Medical University

Mengjing Zhao

Department of Radiology, the First Affiliated Hospital of Wenzhou Medical University

Yuxia Duan

Wenzhou Medical University - Department of Radiology

Gang Li

Wenzhou Medical University - Department of Chemoradiation Oncology

More...

Abstract

Background: MAGEA3 is a member of melanoma antigen family and has been recognized to express in many types of human cancers recently. With the development of monoclonal antibody and cancer-specific vaccine, numerous clinical trials are running against MAGEA3. In spite of that, the prognostic value of MAGEA3 has not been well evaluated, due to the variability of clinical data and lack of clinical trials on the prognostic values. Here we presented a meta-analysis evaluating the prediction value of MAGEA3 to the prognosis of solid and non-solid tumors.

Method: Studies that evaluated MAGEA3 expression using RT-PCR or immunochemistry and report the prognosis with a follow-up for at least 36 months were selected by searching in PubMed. Published data was recorded with access to original data or extracted from Kaplan-Meier curves with GetData Graph Digitizer 2·26 and calculated into odds ratios (OR) for mortality in 3 or 5 years with Mantel-Haenszel random-effect model using Review Manager 5·3 and Vassarstats online, and multiple sensitivity tests were ran in order to evaluate heterogeneity. All the statistical tests were two-sided.

Results: 11 studies were selected including two on lung cancer, two on head and neck squamous cell carcinoma, while others each on pancreatic cancer, neuroblastoma, diffuse large B cell lymphoma, multiple myeloma, primary breast cancer, intrahepatic cholagiocarcinoma and bladder cancer. The median positive rate was 45%. MAGEA3 always combines with worse survival on 3 or 5 years survival. For 3-year survival, OR (odds ratio) =1·97, 95% confidence interval (95%CI) =1·29 to 3·02, P=0·002, while the impact of MAGEA3 on the prediction ability of prognosis seemed heavier, OR (odds ratio) =2·33, 95% confidence interval (95%CI) =1·54 to 3·54, P<0·0001. It was an interesting phenomenon that the correlation between MAGEA3 and squamous carcinoma seemed stronger than adenocarcinoma on 3-year OS while things got a reverse when it came to 5-year OS. We also found that all solid tumors originated from endoderm seemed to enjoy a strongest correlation among all the three germ layers.

Conclusion: In this meta-analysis, we found that the expression of MAGEA3 can connect with worse outcome, and it probably can be a predictor for patients’ prognosis in clinical practice.

Funding Statement: This project was supported by the Medicine and Health Grant from Wenzhou Municipal Science and Technology Bureau (Y20180213) and the Natural Science Foundation of Zhejiang Province (LY20H160009).

Declaration of Interests: The authors declared no conflict of interest.

Keywords: MAGEA3; Cancer/Testis antigen; Prognosis; Outcome; Cancer

Suggested Citation

Jiang, Haoran and Zhao, Lihao and Yang, Han and Zhao, Mengjing and Duan, Yuxia and Li, Gang, MAGAE3 Expression in Solid/Non-Solid Human Tumor: A Meta-Analysis (4/7/2020). Available at SSRN: https://ssrn.com/abstract=3572846 or http://dx.doi.org/10.2139/ssrn.3572846

Haoran Jiang

First Clinical College,Wenzhou Medical University

Lihao Zhao

Department of Chemoradiation Oncology, the First Affiliated Hospital of Wenzhou Medical University

Han Yang

Department of Chemoradiation Oncology, the First Affiliated Hospital of Wenzhou Medical University

Mengjing Zhao

Department of Radiology, the First Affiliated Hospital of Wenzhou Medical University

Yuxia Duan

Wenzhou Medical University - Department of Radiology ( email )

Wenzhou
China

Gang Li (Contact Author)

Wenzhou Medical University - Department of Chemoradiation Oncology ( email )

Zhejiang
China

Click here to go to TheLancet.com

Paper statistics

Abstract Views
59
Downloads
4